FFT, Inflammation, Lipid Metabolism, Blood Pressure and Organ Damage in Patients With Obesity, Chronic Kidney Disease (CKD).

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Collegium Medicum w Bydgoszczy.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
University of Colorado, Denver
Information provided by:
Collegium Medicum w Bydgoszczy
ClinicalTrials.gov Identifier:
NCT01332526
First received: March 31, 2011
Last updated: April 15, 2011
Last verified: March 2011
  Purpose

Fructose intake from added sugars has increased dramatically over the last century and has recently been implicated as potential contributor to metabolic syndrome, obesity, hypertension, inflammation and kidney disease. Fructose differs from the other sugars because, uric acid is generated during its metabolism. Serum uric acid levels have been found to correlate with the intake of fructose and added sugars. In turn, an elevated serum uric acid has also been shown to be associated with increased risk for cardiovascular and metabolic diseases. On the other hand complexity of fructose metabolism in each individuals results of the various magnitude of hyperuricemia induced by fructose intake. The magnitude of uric acid production in each patient may reflect individual predisposition to endogenous urate production in a face of relatively normal fasting uric acid concentration. Therefore the oral fructose tolerance test might reveal an occult purine disturbances which plays casual role in either metabolic disturbances or organ damage.

The aim of this study is to see whether is a relationship between fructose induced hyperuricemia and metabolic disturbances , inflammatory state and organ damage in obese and various stages CKD patients.


Condition
Obesity
Chronic Kidney Disease
Metabolic Syndrome

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Oral Fructose Load Test and Inflammation, Lipid Metabolism, Blood Pressure and Organ Damage in Patients With Obesity, Chronic Kidney Disease With Comparison With Healthy Controls.

Resource links provided by NLM:


Further study details as provided by Collegium Medicum w Bydgoszczy:

Estimated Enrollment: 70
Study Start Date: May 2011
Groups/Cohorts
Patients with BMI> 30 and metabolic syndrome ( ATP III).
Patients with BMI> 30 and metabolic syndrome ( ATP III).
Patient with BMI> 30 without metabolic syndrome.
Patient with BMI> 30 without metabolic syndrome.
Normal healthy control
healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI < 25;normotensives ).
Patients with CKD stage III and uric acid < 7 mg/dl

Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl.

  • without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressives agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)
Patients with CKD stage III and uric acid > 7 mg/dl

Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl

  • without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)
Patient with asymptomatic hyperuricemia
Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function
Hemodialysis patients

Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function Hemodialysis patients.

  • CKD: nondiabetic nephropathy
  • duration hemodialysis 3-48 months
  • Hb-11-13 g/dl
  • well controlled hypertension ( < 140/90 mmHg)
  • without ACEi, ARB, allopurinol treatment
  • residual diuresis will be estimated for last 48 hours-between mid and next dialysis

Detailed Description:

The study will be performed in two experimental groups. Proposed study groups Study I Patients with BMI> 30 and metabolic syndrome. Patient with BMI> 30 without metabolic syndrome. Normal healthy controls. Study II Patients with CKD stage III and uric acid < 7 mg/dl Patients with CKD stage III and uric acid > 7 mg/dl Patient with asymptomatic hyperuricemia and eGFR > 90 ml/min/1.73 m2, , uric acid > 7 mg/dl Hemodialysis patients

Characteristics of the particular patients group- including criteria:

10- 15 participants in each subset of each group age 18-65 y. Gender: females and males in equal proportion. Group I Patients with BMI> 30 and metabolic syndrome ( ATP III). Patient with BMI> 30 without metabolic syndrome. Normal healthy control- healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI < 25;normotensives ).

Group II Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl.

  • without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg) Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl
  • without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)

Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function Hemodialysis patients.

  • CKD: nondiabetic nephropathy
  • duration hemodialysis 3-48 months
  • Hb-11-13 g/dl
  • well controlled hypertension ( < 140/90 mmHg)
  • without ACEi, ARB, allopurinol treatment
  • residual diuresis will be estimated for last 48 hours-between mid and next dialysis Method of investigation All patients and controls ( but hemodialysis) will present after overnight fast. Baseline tests include 24 hr urine collection for: sodium, calcium, phosphorus, creatinine, uric acid, NAG, albumin will be carry out and the same morning fasting sample of blood for: creatinine, cystatin C , uric acid, sodium, glucose, insulin, triglycerides, HDL and LDL cholesterol, calcium, phosphorus, hsCRP. BP will be determined as the mean of three readings taken 5 min apart while sitting. Next in all patients and controls fructose tolerance test will be performed. The test consists of giving 1 gram/kg b.w. of fructose p.o. with blood collection at 0,30,60 and 120 min afterward for serum uric acid determination and uric acid area under the curve will be calculated. The calculated area under curve is the measure of occult uric acid disturbance when compared to controls.

Day before the urine collection the ABPM , BMI, IM (intima media ratio) , renal duplex ultrasound (RI) will be done

Measure BMI, waist circumference

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Study I Patients with BMI> 30 and metabolic syndrome. Patient with BMI> 30 without metabolic syndrome. Normal healthy controls. Study II Patients with CKD stage III and uric acid < 7 mg/dl Patients with CKD stage III and uric acid > 7 mg/dl Patient with asymptomatic hiperuricemia and eGFR > 90 ml/min/1.73 m2, , uric acid > 7 mg/dl Hemodialysis patients

Criteria

Inclusion Criteria:

- Group I Patients with BMI> 30 and metabolic syndrome ( ATP III). Patient with BMI> 30 without metabolic syndrome. Normal healthy control- healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI < 25;normotensives ).

Group II Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl.

  • without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressives agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg) Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl
  • without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)

Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function Hemodialysis patients.

  • CKD: nondiabetic nephropathy
  • duration hemodialysis 3-48 months
  • Hb-11-13 g/dl
  • well controlled hypertension ( < 140/90 mmHg)
  • without ACEi, ARB, allopurinol treatment
  • residual diuresis will be estimated for last 48 hours-between mid and next dialysis

Exclusion Criteria:

  • immunosuppressive agents, ACEi, ARB, allopurinol treatment
  • diabetes mellitus
  • not well controlled hypertension ( > 140/90 mmHg)
  • proteinuria > 3,5 g/24 h
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01332526

Contacts
Contact: Jacek JM Manitius +48525854030 nerka@nerkacpro.pl

Sponsors and Collaborators
Collegium Medicum w Bydgoszczy
University of Colorado, Denver
Investigators
Study Chair: Jacek JM Manitius Department of Nephrology, Hypertension and Internal Diseases Nicolaus Copernicus University in Torun Poland Collegium Medicum in Bydgoszcz
  More Information

No publications provided

Responsible Party: Richard Johnson M.D., Chief, Division of Renal Diseases and Hypertension
ClinicalTrials.gov Identifier: NCT01332526     History of Changes
Other Study ID Numbers: FFT Bydgoszcz
Study First Received: March 31, 2011
Last Updated: April 15, 2011
Health Authority: United States: University of Colorado, Denver

Keywords provided by Collegium Medicum w Bydgoszczy:
FFT
inflammation
lipid metabolism
hyperuricemia
Agents Affecting Uric Acid Metabolism

Additional relevant MeSH terms:
Inflammation
Kidney Diseases
Obesity
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Metabolic Syndrome X
Pathologic Processes
Urologic Diseases
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Renal Insufficiency
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Uric Acid
Immunosuppressive Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protective Agents
Physiological Effects of Drugs
Immunologic Factors

ClinicalTrials.gov processed this record on April 21, 2014